New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
19:17 EDTISISIsis Pharmaceuticals presents data from phase 1 study at AAN meeting
Isis Pharmaceuticals announced that data from the Phase 1 study of ISIS-SMNRx in children with spinal muscular atrophy were presented at the 65th American Academy of Neurology Annual Meeting by Dr. Claudia Chiriboga, from Columbia University Medical Center. In the presentation, Dr. Chiriboga reported that, in this single-dose, open-label study, ISIS-SMNRx was well tolerated in children with SMA at all dose levels tested and that improvements were observed in Hammersmith scores, a measure of muscle function, in a number of the children. "We are cautiously optimistic with the observed improvements in muscle function in the higher dose cohort, however, we will need further clinical data from a controlled study to assess the safety and activity of this drug in patients with SMA. We plan to have additional clinical data from our ongoing multiple-dose study in children with SMA by late 2013 or early 2014. We also plan to initiate a Phase 2/3 program in infants this year and a Phase 2/3 study in children in the first half of 2014," said Stanley T. Crooke, M.D., Ph.D., chairman of the board and chief executive officer at Isis.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
07:09 EDTISISIsis Pharmaceuticals initiates pivotal Phase 3 study evaluating ISIS-SMN
Subscribe for More Information
November 20, 2014
07:24 EDTISISGoldman to hold a conference
Subscribe for More Information
06:40 EDTISISIsis Pharmaceuticals price target raised to $62 from $53 at Piper Jaffray
Subscribe for More Information
November 18, 2014
15:48 EDTISISGenzyme, Isis present KYNAMRO data at AHA meeting
Genzyme, a Sanofi (SNY) company, and Isis Pharmaceuticals (ISIS) announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
November 14, 2014
15:41 EDTISISIsis Pharmaceuticals management to meet with Piper Jaffray
Meeting to be held in Kansas City, MO on November 18 hosted by Piper Jaffray.
November 13, 2014
05:34 EDTISISAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use